Quantum BioPharma MS drug candidate moves toward phase 2 trials
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/3/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
- Analysis-Excommunications show a Pope Leo unafraid of making firm decisions
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Canaccord Starts Infleqtion, Inc (INFQ) at Buy
- Jersey Mike's Subs files for IPO on NYSE under ticker JMKE
- AXT-Tongmei signs 3-year wafer supply deal with Coherent
Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy
June 25, 2026 8:30 AM EDTNEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- via BioMedWire Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) today announces its placement in an editorial published by... More
